CATB - カタバシス・ファ―マシュ―ティカルズ （Catabasis Pharmaceuticals Inc.） カタバシス・ファ―マシュ―ティカルズCATBのチャート
CATBの企業情報
| symbol | CATB |
|---|---|
| 会社名 | Catabasis Pharmaceuticals Inc （カタバシス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Catabasis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART) a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate a non-steroidal anti-inflammatory drug and the omega-3 fatty acid docosahexaenoic acid (DHA) a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA. カタバシス・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品企業。同社独自の「SMART」技術に基づき、治療薬を開発、製造、販売する。この技術は、複数の関連疾患の経路に複数の生物学的タ―ゲットの組み合わせにより疾患を治療するのが狙い。同社は筋ジストロフィ―を治療する薬を扱う。本社はマサチュ―セッツ州。 At Catabasis Pharmaceuticals, the mission is to bring hope with life-changing therapies to patients and families affected by rare diseases. Its lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. |
| 本社所在地 | One Kendall Square Bldg. 1400E Suite B14202 Cambridge MA 02139 USA |
| 代表者氏名 | Kenneth M. Bate ケネス・ベイト |
| 代表者役職名 | Co-Chairman of the Board |
| 電話番号 | +1 617-349-1971 |
| 設立年月日 | 39600 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 36人 |
| url | www.catabasis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/catb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -26.44500 |
| 終値（lastsale） | 0.776 |
| 時価総額（marketcap） | 55125813.144 |
| 時価総額 | 時価総額（百万ドル） 49.12307 |
| 売上高 | 売上高（百万ドル） 0.50000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 0.02307 |
| 当期純利益 | 当期純利益（百万ドル） -26.64500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Catabasis Pharmaceuticals Inc revenues was not reported. Net loss decreased 5% to $14.1M. Lower net loss reflects Interest expense decrease of 67% to $90K (expense) Other income net increase from $23K to $159K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.49. |
CATBのテクニカル分析
CATBのニュース
Global Duchenne Muscular Dystrophy Drugs Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Akashi Therapeutics Inc, Capricor Therapeutics Inc, Biogen Inc, Antisense Therapeutics Ltd, Biophytis SAS, Beech Tree Labs Inc, CRISPR Therapeutics, BioMarin Pharmaceutical Inc, Bioleaders Corp, Catabasis Pharmaceuticals Inc, Eloxx Pharmaceuticals Inc, Fulcrum Therapeutics In 2021/07/24 00:25:49 Jumbo News
The report on Global Duchenne Muscular Dystrophy Drugs Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a []
Protein Glutamine Gamma Glutamyltransferase 2 Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Catabasis Pharmaceuticals Inc, Zedira GmbH 2021/07/23 01:33:19 Jumbo News
This report studies the Protein Glutamine Gamma Glutamyltransferase 2 Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Protein Glutamine Gamma Glutamyltransferase 2 []
Take This As A Wake-Up Call: Jupai Holdings Limited (NYSE:JP), Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) 2021/07/12 22:43:33 Stock Equity
Jupai Holdings Limited (JP) with the stream of -2.20% also noticed, India Catabasis Pharmaceuticals, Inc. (CATB) encountered a rapid change of -1.24% in the last hour of Mondays trading session. The post Take This As A Wake-Up Call: Jupai Holdings Limited (NYSE:JP), Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) appeared first on Stocks Equity .
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition 2021/06/30 06:24:41 Seeking Alpha
Blustering Stock: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), Great Panther Mining Limited (AMEX:GPL) 2021/06/24 23:18:47 Stock Equity
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) with the stream of 9.30% also noticed, India Great Panther Mining Limited (AMEX:GPL) encountered a rapid change of 0.07% in the last hour of Thursdays trading The post Blustering Stock: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), Great Panther Mining Limited (AMEX:GPL) appeared first on Stocks Equity .
Catabasis Pharmaceuticals (NASDAQ:CATB) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS 2021/03/13 00:20:07 Transcript Daily
Catabasis Pharmaceuticals (NASDAQ:CATB) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07), Fidelity Earnings reports. Catabasis Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, hitting $3.37. The company had a trading volume of 27,015 shares, compared […]
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update 2021/03/11 21:10:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences 2021/03/02 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
Catabasis Pharmaceuticals Acquires Quellis Biosciences | FinSMEs 2021/02/01 09:31:35 FinSMEs
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, acquired Quellis Biosciences, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases
88 Biggest Movers From Friday 2021/02/01 09:07:57 Benzinga
Gainers Siebert Financial Corp. (NASDAQ: SIEB ) shares climbed 121.6% to close at $8.22 on Friday on heavy volume. Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB ) climbed 70.8% to close at $4.15 after the company announced the acquisition of Quellis Biosciences. GameStop Corp. (NYSE: GME ) shares added 67.9% to close at $325.00 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest. The company’s stock dropped over 44% on Thursday. Novavax, Inc. (NASDAQ: NVAX ) surged 64.9% to close at $220.94 after the company said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom. AMC Entertainment Holdings, Inc. (NYSE: AMC ) surged 53.7% to close at $13.26 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest.
Catabasis Pharmaceuticals (NASDAQ:CATB) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS 2021/03/13 00:20:07 Transcript Daily
Catabasis Pharmaceuticals (NASDAQ:CATB) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07), Fidelity Earnings reports. Catabasis Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, hitting $3.37. The company had a trading volume of 27,015 shares, compared […]
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update 2021/03/11 21:10:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences 2021/03/02 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
Catabasis Pharmaceuticals Acquires Quellis Biosciences | FinSMEs 2021/02/01 09:31:35 FinSMEs
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, acquired Quellis Biosciences, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases
88 Biggest Movers From Friday 2021/02/01 09:07:57 Benzinga
Gainers Siebert Financial Corp. (NASDAQ: SIEB ) shares climbed 121.6% to close at $8.22 on Friday on heavy volume. Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB ) climbed 70.8% to close at $4.15 after the company announced the acquisition of Quellis Biosciences. GameStop Corp. (NYSE: GME ) shares added 67.9% to close at $325.00 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest. The company’s stock dropped over 44% on Thursday. Novavax, Inc. (NASDAQ: NVAX ) surged 64.9% to close at $220.94 after the company said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom. AMC Entertainment Holdings, Inc. (NYSE: AMC ) surged 53.7% to close at $13.26 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest.